AI chatbot plus home HPV self-sampling to boost cervical screening participation
Official title: Artificial Intelligence-assisted Decision-making to Improve Women's Participation to Cervical Cancer Screening in Occitanie Region-France
Run by International Agency for Research on Cancer · NCT05286034 · Data updated 2026-11-12
This project will try to see if sending HPV self-sampling kits to women aged 30–65 in low-income areas together with a multi-language AI chatbot decision aid increases screening uptake among women who did not respond to an initial invitation.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Years to 65 Years |
| Sex | Women only |
| Enrollment | 3000 (estimated) |
| Sponsor | International Agency for Research on Cancer Academic / other |
| Locations | 1 site (Carcassone) |
| Status | Recruiting |
| Started | November 3, 2025 |
| Main results expected | July 31, 2026 |
| Study ends | August 18, 2026 |
| Registry record updated | March 27, 2026 |
| Trial ID | NCT05286034 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women aged 30–65 who live in selected deprived clusters in Occitanie, have not had a Pap smear in the past 4 years, and did not respond to a first invitation to clinician-collected HPV testing.
✕Probably not a fit
Women outside the target age range, those recently screened or already scheduled for screening, pregnant women, those with hysterectomy including the cervix, or women currently undergoing evaluation or treatment for cervical abnormalities are not expected to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This cluster randomized study targets non-responding women aged 30–65 living in deprived clusters of the Occitanie region. Selected clusters will receive mailed HPV self-sampling kits combined with access to a multi-language decision aid delivered via an artificial intelligence-based chatbot on mobile channels, while control clusters receive usual invitation procedures. The primary outcome is return rate of HPV self-sampling; secondary outcomes include follow-up and management of women who test HPV positive. The intervention is tailored for women with lower educational attainment to address knowledge, perception, and logistical barriers to screening.
Why it matters
Potential benefit: If successful, the approach could raise screening rates and help detect cervical precancers earlier in underserved women, reducing equity gaps in care.
How similar studies have gone: Previous trials have shown that mailed HPV self-sampling kits can increase participation, while multi-language AI chatbot decision aids are a newer, less-tested addition in randomized settings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: eligible women will be: * aged 30-65 * did not perform a pap smear in the last 4 years * are living in deprived clusters in the Occitanie region. * did not answer to a first "invitation" letter to perform a clinician-collected HPV testing Exclusion criteria: ineligible women will be those: * outside the target age group * had a Pap smear in the past 3 years * had hysterectomy including cervix * are pregnant * already scheduled a screening appointment or had just attended a HPV screening * had a cervical abnormality that was under exploration and/or treatment. * participated to the study pilot
Where it's running
-
Centre Régional de Coordination des Dépistages des Cancers-Centre d'Occitanie
Carcassone, France Recruiting
Study contacts
- Study coordinator: Farida Selmouni, Dr
- Email: selmounif@iarc.who.int
- Phone: + 33 4 72 73 84 99
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HPV self-sampling to improve cervical screening for women in Zaporizhzhia during the war
This project will test whether giving women aged 30–60 in Zaporizhzhia HPV self-sampling kits can keep cervical screening going when clinic access is disrupted by the war.
-
Patient-centered cervical cancer screening and treatment linkage program in Nairobi
This project will try a multi-part care approach (DADA LINK) using care coordinators and an mHealth app to help women ages 25–49 in Nairobi get screened for cervical cancer and linked to treatment when needed.
-
Cervical screening and care options for women living with HIV who test positive for high-risk HPV
This study tests different ways to screen and manage high-risk HPV in women with HIV to see what might work best for them.
-
Hydrogel spacer to protect the rectum during cervical cancer radiotherapy
This study tests whether placing an absorbable hydrogel spacer between the cervix/vagina and rectum before definitive radiotherapy can reduce rectal radiation exposure for women with cervical cancer.
-
How cinema sessions during chemotherapy might help cervical cancer patients
We’re testing if watching films during chemotherapy helps cervical cancer patients feel less anxious and improve quality of life.
-
One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy
This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.